Chimeric Therapeutics Limited (ASX:CHM) has confirmed that all patients dosed in the first patient cohort in City of Hope’s phase 1 CLTX CAR T cell clinical trial have advanced beyond the 28-day follow-up period without experiencing dose-limiting toxicities.
Achievement of this safety milestone for all patients in cohort 1 enables the trial to advance to the second dosing level, which will administer CLTX CAR T cells by two routes (intratumoral (ICT) and intracranial intraventricular (ICV)) at a total dose of 88 x 106 CAR T cells.
“Significant milestone”
Chimeric chief operating officer Jennifer Chow said: “We are very pleased to have reached this significant milestone with our CLTX CAR T cell therapy as it enables us to advance the development of this important therapy for patients with progressive or recurrent Glioblastoma.
“We look forward to further progressing the development of CLTX CAR T and to providing updates as we seek to bring the promise of cell therapy to life for more patients with cancer.”
Study objectives
The CLTX CAR T cell clinical trial is taking place at City of Hope, a world-renowned cancer research and treatment centre near Los Angeles.
The objective of this study is to evaluate the safety and maximum tolerated dose of Chimeric’s Chlorotoxin CAR T (CLTX CAR T) cell therapy in patients with recurrent or progressive glioblastoma (GBM).
The Phase 1 study aims to enrol 18-36 patients with MMP2+ recurrent or progressive GBM across 4 dose levels.
Study objectives are to evaluate the safety and efficacy of CLTX CAR T cells and to establish recommended dosing for a phase 2 trial.